Clostridium difficile is responsible for 15-25% of cases of antibiotic-associated diarrhea (AAD) and for virtually all cases of antibiotic-associated pseudomembranous colitis (PMC). This anaerobic bacterium has been identified as the leading cause of nosocomial infectious diarrhea in adults and can be responsible for large outbreaks. Nosocomial C. difficile infection results in an increased length of stay in hospital ranging from 8 to 21 days. Risk factors for C. difficile-associated diarrhea include antimicrobial therapy, older age (>65 years), antineoplastic chemotherapy and length of hospital stay. Other interventions with high risk associations are enemas, nasogastric tubes, gastrointestinal surgery and antiperistaltic drugs. Prospective studies have shown that nosocomial transmission of C. difficile is frequent but often remains asymptomatic. Patients can be contaminated from environnemental surfaces, shared instrumentation, hospital personnel hands and infected roommates. Once an outbreak starts, C. difficile may be spread rapidly throughout the hospital environment where spores may persist for months. Measures that are effective in reducing incidence of C. difficile infections and cross-infection include: (i) an accurate and rapid diagnosis, (ii) appropriate treatment, (iii) implementation of enteric precautions for symptomatic patients, (iv) reinforcement of hand-washing, (v) daily environmental disinfection, and (vi) a restrictive antibiotic policy. C. difficile is a common cause of infectious diarrhea and should be therefore systematically investigated in patients with nosocomial diarrhea.
IN TR ODUC T ION
Clostridium difficile is a spore-forming Gram-positive anaerobic bacillus that was first isolated from stools of neonates in 1935. Forty years later, this bacterium has been recognised as the main cause of pseudomembranous colitis (PMC) and antibioticassociated colitis and diarrhea-the C. difficile-associated disease (CDAD) [1, 2] . Since then, studies concerning the pathogenesis, diagnosis and treatment of C. difficile-associated infections have increasingly been reported. In this paper, we review the current knowledge of epidemiological features related to C. difficile.
CL INIC AL PR E SEN TAT ION S
Clinical presentations of C. difficile range from mild diarrhea to life-threatening PMC with megacolon and possible perforation.
C. difficile toxin B has been isolated from stools of more than 95% of PMC cases and of 15-25% cases of antibiotic-associated diarrhea (AAD) (Table 1) [1] . During the past 20 years, toxigenic C. difficile has emerged as a major cause of nosocomial diarrhea and has been responsible for large outbreaks in hospital settings [3, 4] . In many hospitals, C. difficile is the most common enteropathogen isolated from stool cultures.
However, isolation of C. difficile must be interpreted with caution because asymptomatic carriage is usually observed in less than 3% of healthy adults [1] . Carriage rates are higher in patients with previous hospitalisation or in patients who have previously received antibiotics. It is not known if this carriage rate represents transient colonisation or a component of the stable flora.
Pathogenesis
More than 90% of C. difficile infections occur after or during antibiotic treatment. Antibiotics act by disrupting the normal colonic flora, allowing C. difficile, from endogenous or exogenous origins, to establish itself in the colon and proliferate. If the strain is toxigenic, toxins A and B are produced simultaneously in almost all cases, causing fluid secretion, inflammation
